EDGAR Filing Documents for 0001485003-17-000132

Form 8-K - Current report:

SEC Accession No. 0001485003-17-000132

Filing Date

2017-11-03

Accepted

2017-11-03 16:57:07

Documents

Period of Report

2017-11-01

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	ebio-form8xkclosingofoffer.htm	8-K	44365
2	EXHIBIT 1.1	ex11ebio-underwritingagree.htm	EX-1.1	433294
3	EXHIBIT 4.1	ex41ebiopre-fundedwarrant1.htm	EX-4.1	110733
4	EXHIBIT 4.2	ex42ebiowarrant130oct2017f.htm	EX-4.2	115480
5	EXHIBIT 99.1	ex991ebio-pricingrelease11.htm	EX-99.1	11737
6	EXHIBIT 99.2	ex992ebio-closingrelease11.htm	EX-99.2	11549
7		elevenlogoa01.jpg	GRAPHIC	8456
8		elevenlogoa03.jpg	GRAPHIC	8456
	Complete submission text file	0001485003-17-000132.txt		751832

Mailing Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142

Business Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142 617-444-8550

Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 262025616 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36296 | Film No.: 171177191
SIC: 2834 Pharmaceutical Preparations